Prosecution Insights
Last updated: April 19, 2026
Application No. 35/520,954

Bottle for cosmetics packaging

Non-Final OA §102§103
Filed
Apr 10, 2024
Examiner
BIRDWELL, AMANDA KAY
Art Unit
2922
Tech Center
2900
Assignee
Sirok Inc.
OA Round
3 (Non-Final)
100%
Grant Probability
Favorable
3-4
OA Rounds
2y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 100% — above average
100%
Career Allow Rate
94 granted / 94 resolved
+40.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
4 currently pending
Career history
98
Total Applications
across all art units

Statute-Specific Performance

§103
5.3%
-34.7% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
70.2%
+30.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 94 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s Response Acknowledgement is here made of the Applicant’s Remarks and Amendment of 10/16/2025. The merits of the application have been carefully reconsidered in view of the Remarks and Amendment of 10/16/2025. Applicant’s Response to Claim Rejection - 35 USC § 102(a)(1) The declaration under 37 CFR 1.130(a) filed on 10/16/2025 is sufficient to overcome the rejection of the claim based on 35 U.S.C. 102(a)(1). Applicant has filed a declaration of attribution under 37 CFR 1.130(a) to invoke the 102(b)(1)(A) exception. Per the declaration, the claimed design originated with one or more members of the inventive entity, as listed on the application (whose signature is on the declaration). As such, the subject matter disclosed in the prior art was obtained directly from the inventor in the present application. Since the declaration disqualifies the prior art by establishing the subject matter disclosed was owned by the inventor, and was made 1 year or less before the effective filing date of the claimed design, the rejection under 35 U.S.C. 102(a)(1) has been overcome. However, additional prior art that is substantially the same as that of the claimed design has been discovered. See Rejection below. Claim Rejection - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: “A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.” The claim is rejected under 35 U.S.C. 103 as being unpatentable over Examiner's cited Non-Patent Document “U”, FAS THE BLACK AC OIL SERUM (hereinafter FAS). Although the invention is not identically disclosed or described as set forth in 35 U.S.C. 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a designer having ordinary skill in the art to which the claimed invention pertains, the invention is not patentable. The FAS Design teaches a bottle with a dropper-style dispenser, having an overall appearance with design characteristics that are visually similar to those of the claimed design, in showing a substantially cylindrical bottle with an organic undulating surface, angular shoulders, and a dropper-style attachment. See comparison below. The claimed design differs from the FAS design in that is shown in a different color. PNG media_image1.png 660 995 media_image1.png Greyscale The difference in the change of color from the claimed design to FAS is not a patentable distinction. “Patentability of design may not rest on color alone. The differences in color are not sufficient to patentably distinguish the claimed design over the prior art, as selection of different color would not produce any basic alteration or unexpected appearance.” In re Iknayan et. Al. 124 USPQ 507 (1960). Additionally, the variation in descriptive copy is considered to be de minimis. A difference is de minimis in nature when its visual effect is unrelated to the overall aesthetic appearance of the design – so minimal or so minor that it has insignificant impact on the overall visual impression. Differences may be considered patentably insufficient when they are de minimis to a designer of ordinary skill in the art. These differences are considered to be differences that are too insignificant within the scope of the entire design to warrant a patent, (see In re Lapworth, 172 USPQ 129 (C.C.P.A. 1971 and In re Lamb, 48 CCPA 817, 286 F.2d 610, 128 USPQ 539 (1961)). Therefore, it would have been obvious to a designer of ordinary skill before the effective filing date of the present claimed invention to modify the black color of the FAS Design to be white, and modify the descriptive copy to read “THE BLACK BRIGHT SERUM”. Because such changes are not representative of innovation, each difference alone or together, fails to be anything other than an obvious design choice. It is well settled that it is unobviousness in the overall appearance of the claimed design, when compared with the prior art, rather than minute details or small variations in design as appears to be the case here, that constitutes the test of design patentability. See In re Frick, 275 F.2d 741, 125 USPQ 191 (CCPA 1960) and In re Lamb, 286 F.2d 610, 128 USPQ 539 (CCPA 1961). Reply Reminder Applicant is reminded that any reply to this communication must be signed either by a patent practitioner (i.e., a patent attorney or agent registered to practice before the United States Patent and Trademark Office) or by the applicant. If the applicant is a juristic entity, the reply must be signed by a patent practitioner. See 37 CFR 1.33(b). Discussion of the Merits of the Application All discussions between the applicant and the examiner regarding the merits of a pending application will be considered an interview and are to be made of record. See MPEP 713. The examiner will not discuss the merits of the application with applicant’s representative if the representative is not registered to practice before the USPTO. Appointment as applicant’s representative before the International Bureau pursuant to Rule 3 of the Common Regulations under the Hague Agreement does NOT entitle such representative to represent the applicant before the USPTO. Furthermore, an applicant that is a juristic entity must be represented by a patent attorney or agent registered to practice before the USPTO. Additional information regarding interviews is set forth below. Telephonic or in person interviews: A telephonic or in person interview may only be conducted with an attorney or agent registered to practice before the USPTO (“registered practitioner”) or with a pro se applicant (an applicant who is the inventor and who is not represented by a registered practitioner). The registered practitioner may either be of record or not of record. To become “of record”, a power of attorney (POA) in accordance with 37 CFR 1.32 must be filed in the application. Form PTO/AIA /80 “Power of Attorney to Prosecute Applications Before the USPTO”, available at https://www.uspto.gov/patent/forms/forms-patent-applications-filed-or-after-september-16-2012, may be used for this purpose. See MPEP 402.02(a) for further information. Interviews may also be conducted with a registered practitioner not of record provided the registered practitioner can show authorization to conduct an interview by completing, signing and filing an “Applicant Initiated Interview Request Form” (PTOL-413A) (available at the USPTO web page indicated above). See MPEP 405. For acceptable ways to submit forms to the USPTO, see “When Responding to Official USPTO Correspondence” below. Responding to Official USPTO Correspondence The USPTO transacts business in writing. All replies must be signed in accordance with 37 CFR 1.33(b). Pursuant to 37 CFR 1.33(b)(3), a reply submitted on behalf of a juristic applicant must be signed by an attorney or agent registered to practice before the USPTO. Applicants may submit replies to Office actions only by: Online via the USPTO's Electronic Filing System‐Web (EFS‐Web) (Registered eFilers only) https://www.uspto.gov/patents/apply Mail: Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313‐1450 Facsimile to the USPTO's Official Fax Number (571‐273‐8300) Hand‐carry to USPTO's Alexandria, Virginia Customer Service Window https://www.uspto.gov/patents/maintain/responding-office-actions Conclusion The claim stands rejected under 35 U.S.C. 102(a)1. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMANDA KAY BIRDWELL whose telephone number is (571)272-9125. The examiner can normally be reached Mon-Fri 8:30-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, Primary Examiner Barbara Fox can be reached at (571)272-4456, or, the examiner’s supervisor, Rich Edgar, can be reached at (571)272-4816. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.K.B./ Examiner, Art Unit 2931 /BARBARA FOX/Supervisory Patent Examiner, Art Unit 2936
Read full office action

Prosecution Timeline

Apr 10, 2024
Application Filed
Mar 04, 2025
Non-Final Rejection — §102, §103
May 30, 2025
Response Filed
May 30, 2025
Response after Non-Final Action
Jun 04, 2025
Final Rejection — §102, §103
Oct 16, 2025
Response after Non-Final Action
Oct 16, 2025
Response after Non-Final Action
Nov 24, 2025
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent D1119604
Bottle
2y 5m to grant Granted Mar 24, 2026
Patent D1119091
Perfume bottle
2y 5m to grant Granted Mar 17, 2026
Patent D1116828
Bottle cap
2y 5m to grant Granted Mar 10, 2026
Patent D1108269
Eyedrop Bottle
2y 5m to grant Granted Jan 06, 2026
Patent D1103778
PACKAGING CONTAINER
2y 5m to grant Granted Dec 02, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
100%
Grant Probability
99%
With Interview (+0.0%)
2y 3m
Median Time to Grant
High
PTA Risk
Based on 94 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month